Are you Dr. Oh?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 118 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3410 Worth St
Dept of Gynecologic Oncology
Dallas, TX 75246Phone+1 214-370-1301Fax+1 214-370-1318
Summary
- Dr. Jonathan Oh, MD is an obstetrician/gynecologist in Dallas, Texas. He is currently licensed to practice medicine in Texas. He is affiliated with Texas Health Presbyterian Hospital Dallas, Medical City Dallas, and Dallas Medical Center.
Education & Training
- University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2001 - 2004
- University of Texas Southwestern Medical CenterResidency, Obstetrics and Gynecology, 1997 - 2001
- University of Texas Southwestern Medical SchoolClass of 1997
Certifications & Licensure
- TX State Medical License 1998 - 2026
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Publications & Presentations
PubMed
- 161 citationsSynchronous primary cancers of the endometrium and ovary: a single institution review of 84 casesPamela T. Soliman, Brian M. Slomovitz, Russell Broaddus, Charlotte C. Sun, Jonathan C. Oh
Gynecologic Oncology. 2004-08-01 - 74 citationsPhase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.Jonathan Oh, Minal A. Barve, Carolyn M. Matthews, E. Colin Koon, Thomas P. Heffernan
Gynecologic Oncology. 2016-12-01 - 69 citationsGemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.Rodney P. Rocconi, Elizabeth A. Grosen, Sharad A. Ghamande, John K. Chan, Minal A. Barve
The Lancet. Oncology. 2020-12-01